Search Studies

Official Title Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Purpose

The purpose of this study is to examine longitudinal changes in HIV-1 reservoirs among participants with HIV-1 who are either currently receiving antiretroviral therapy (ART) or who received ART previously. Participants will undergo blood and hair sample collections for immunologic, virologic, and pharmacologic evaluations to study HIV-1 reservoirs in the body.

Could this study be right for you?

This study is currently only enrolling in Group 6 which includes participants who acquired HIV while taking long-acting cabotegravir (CAB).

Age Range

18 years and up

Official Title A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission

Purpose

The purpose of this study is to evaluate the safety and efficacy of combination bNAbs in addition to ART initiated during acute HIV infection and to evaluate the impact on HIV viral reservoirs.

Could this study be right for you?

• Newly diagnosed HIV+ individuals who have not yet started antiretroviral therapy (ART)
• Willingness to start ART at enrollment
• Ability and willingness to participate in scheduled study visits and analytic treatment interruption (ATI)
• Weight <115kg

Age Range

18 - 70 years

Official Title A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease

Purpose

This study will evaluate the safety and efficacy of tecovirimat for the treatment of human monkeypox virus (HMPXV) disease.

Could this study be right for you?

• Lab-confirmed OR suspected HMPXV infection
• At least one active skin lesion, mouth lesion, or proctitis with or without visible ulcers
• HMPXV illness of <14 days duration prior to study entry

Age Range

18 years and up

Official Title Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) vaccine, in HIV-1 Infected Adults on suppressive ART

Purpose

The goal of this research study is to see if an investigational vaccine called Trimer 4571 is safe and well tolerated. Additionally, researchers will see if it will help the immune system produce broadly neutralizing antibodies (bNAbs) against HIV. bNAbs are a type of antibody that can recognize and block many types of HIV from entering healthy cells. Trimer 4571 is a vaccine designed to stimulate the development of bnAbs against HIV.

Could this study be right for you?

• On ART for at least 24 months
• HIV RNA <50 for at least 24 months
• CD4 count ≥200
• Known to have started ART during acute HIV infection
• BMI <40kg/m2

Age Range

18 years and up

Official Title A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1

Purpose

This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).

Could this study be right for you?

• Individuals with HIV who started treatment during acute HIV infection
• No known ART interruption >14 consecutive days since ART initiation
• Willingness to participate in analytic treatment interruption
• CD4 count ≥500 within 60 days to study entry
• HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry

Age Range

18 years and up

Official Title A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Purpose

This study will evaluate the safety, tolerability, and efficacy of N-803 with or without bNAbs, to induce HIV-1 control during an analytic treatment interruption (ATI).

Could this study be right for you?

• HIV RNA <50 for at least 96 weeks
• On a stable ART regimen for at least 96 weeks
• CD4 count above 500
• No known history of CD4 count below 200
• Willingness to participate in analytic treatment interruption (ATI)

Age Range

18 - 70 years

Official Title State of Ohio Adversity and Resilience Study (SOAR)- Deep Phenotyping

Purpose

The purpose of this study is to develop effective mental health and preventing suicide and substance use disorder, we must better understand risks, which lead to mental illness, and resilience, which allows us to grow even in presence of adversity. This study is looking at how people live and how they deal with distress, depression or drugs and alcohol in Ohio. Family members living in Ohio are asked to participate.

Could this study be right for you?

Eligibility:

Inclusion criteria:

• Adults, age 18-72, and adolescents, age 12-17.

Exclusion criteria:

• Inability to functionally communicate in English.
• Unwilling/unable to sign informed consent or assent document or obtain parental authorization from a parent or legal guardian (subjects <18 years old).
• Inability to understand/follow instructions for study procedures.
• Participants without at least 1 other family member who is willing to participate
  • The definition of family member is subjective to the participant and may not be a blood relative.

Age Range

12 - 72 years

Official Title Ohio Mood Disorder Registry and Repository

Purpose

Mood disorders like Major Depressive Disorder and Bipolar Disorder can be chronic, recurrent illnesses. Our treatments to date can help many people but are often trial and error, and continuity and access to care form major barriers. Our purpose is to create a research registry and repository of individuals with mood disorders who are willing to provide clinical data yearly, and who are willing to be contacted to participate in current and future studies of mood disorders.

Could this study be right for you?

Inclusion Criteria

• 8-70 years of age.
• Fluency or advanced conversational English abilities, by self-report.
• Eligible individuals will have a history of two or more mood disorder episodes (depression events of at least 2 weeks meeting 5 of the criteria for major depressive disorder).

Exclusion Criteria

• Head injury with loss of consciousness of five minutes or greater.
• Hospitalization for drug-related concerns.
• Evidence of intellectual disability.
• Diagnosis of a developmental condition like autism spectrum disorder.
• Evidence of psychosis outside of a mood episode (e.g., schizophrenia).
• Hospitalization or infusion for eating condition.

Age Range

8 - 70 years

Purpose

This study aims at preserving residual hearing and assessing outcomes in cochlear implant patients.

Could this study be right for you?

• Sensorineural hearing loss in both ears acquired after birth
• Better hearing in the low frequencies in the ear to be implanted
• Severe to profound hearing loss in the mid-to-high frequencies in the ear to be implanted
• English-speaking

Inclusion Criteria varies, please contact Study Coordinator. 

Age Range

18 - 79 years

Official Title A Single-Stage, Adaptive, Open-Label Dose Escalation Safety Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MR- guided Infusion into the Midbrain in Pediatric Patients with AADC Deficiency

Purpose

The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency, and to see if there is a demonstration of effective restoration of AADC function by assays of CSF neurotransmitter metabolites and F-DOPA PET imaging, as allowed by subject’s ability to travel to undergo follow-up visits.

Could this study be right for you?

Inclusion Criteria

• Diagnosis of AADC deficiency from genetic test and CSF/blood enzyme test
• Failed to derive adequate benefit from standard medical therapy as judged by presence of residual oculugyric crises and developmental delay.
• Documented history of motor developmental delay, with inability to walk independently without support by age 18 months.
• Both parents (or legal guardians) must give their consent for their child’s participation in the study parents unless (i.) one parent is deceased, unknown or incompetent; (ii.) one parent is not reasonably available; or (iii.) one parent has responsibility for the care and custody of the child.

Inclusion Criteria varies, please contact Study Coordinator for more information.

Exclusion Criteria

• Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
• Previous stereotactic neurosurgery.
• Coagulopathy, or need for ongoing anticoagulant therapy.
• Receipt of any investigational agent within 60 days prior to Baseline and during study participation.

Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

2 years and up

Official Title CareNet: An Interactive Digital Tool to Assess Informal Caregiving Networks of Older Adults with Dementia

Purpose

We are interested in understanding the dynamics of caregiving when multiple caregivers are involved in caring for an older adult with memory problems. We would like to interview the primary caregiver in a brief one-time interview about their thoughts and experiences in providing care for an older adult with memory problems. 

Could this study be right for you?

Participants must be:

• An unpaid caregiver of an older adult with memory loss problems
  • The older adult must be 65 years or older
  • The older adult must not live in a residential care/assisted living facility
• Able to identify at least one other unpaid caregiver for the older adult with memory loss problems
• Able to communicate in English

Age Range

18 years and up

Official Title Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

Purpose

The purpose of this study is to determine whether spinal cord stimulation (SCS) will reduce pain in patients with painful Diabetic Peripheral Neuropathy (DPN).

Could this study be right for you?

 

Inclusion Criteria:

• Over 18 years old
• Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
• Diagnosis of medically refractory pain secondary to diabetic neuropathy
• Presence of pain for 12 months

Exclusion Criteria:

• Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
• Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
• Coagulopathy that cannot be corrected
• Unable to discontinue blood thinning medications

Inclusion and Exclusion Criteria varies, please contact Study Coordinator. 

Age Range

18 years and up